DIPNA PHARMACHEM LIMITED

BSE: DPL543594ISIN INE0MC401013

Healthcare
Pharmaceuticals

Share price

₹3.99-0.02 (-0.50%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹19.92
52W low: ₹3.62
Off 52W high: -79.97%
1M return: -6.78%
3M return: -7.64%
6M return: -51.16%
1Y return: -79.64%
20D avg volume: 47,100
50 DMA: ₹4.57
200 DMA: ₹7.88

Key ratios Standalone

Market cap: ₹10.49 Cr
Current price: ₹3.99
52W high / low: ₹19.92 / ₹3.62
Face value: ₹10.00
P/E: 5.12
P/B: 0.17
EPS (TTM): ₹0.78
Book value / share: ₹23.70
ROE: —
ROCE: 6.90%
Operating margin: —
Net margin: —
Debt / equity: 0.21
Net debt: ₹12.35 Cr
Interest cover: 3.42
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: -56.6 days

Financials

Metric	Q1 FY27	Q4 FY26	Q2 FY26	Q4 FY25	Q4 FY24
Income statement
	20.33	2.02	—	—	—
	3.46	0.03	—	—	—
	23.79	2.05	—	—	—
	23.27	1.83	—	—	—
	0.00	0.00	—	—	—
	18.90	13.54	—	—	—
	0.09	0.10	—	—	—
	0.31	0.23	—	—	—
	0.00	0.00	—	—	—
	3.89	3.37	—	—	—
	0.52	0.22	—	—	—
	0.00	0.00	—	—	—
	0.52	0.22	—	—	—
	0.13	0.04	—	—	—
	0.39	0.18	—	—	—
	0.15	0.07	—	—	—
Key metrics
	0.83	0.45	—	—	—
	4.10%	22.30%	—	—	—
	1.90%	8.90%	—	—	—
	—	0.60%	—	—	—

Metric	FY26	FY25	FY24
Income statement
	129.08	124.92	164.34
	0.03	0.01	0.00
	129.11	124.93	164.34
	125.56	123.51	162.92
	0.00	0.00	—
	122.37	103.78	176.35
	0.41	0.41	0.44
	1.46	2.02	2.00
	0.01	0.01	0.02
	16.19	7.34	2.55
	3.54	1.42	1.42
	0.00	—	—
	3.54	1.42	1.42
	0.91	0.45	0.33
	2.63	0.97	1.08
	1.00	0.41	—
Key metrics
	5.01	3.45	3.44
	3.90%	2.80%	2.10%
	2.00%	0.80%	0.70%
	6.90%	7.30%	—
	3.30%	-24.00%	—
	171.10%	-10.20%	—
	-18.36	-9.21	—
	-6.97	-9.47	—
	0.21	—	—
	12.35	—	—
	-56.6	-6.0	—
Balance sheet
	205.63	132.38	—
	154.09	132.33	—
	0.86	0.43	—
	48.00	46.28	—
	42.33	27.43	—
	62.57	58.19	—
	0.07	0.05	—
	110.34	75.73	—
	133.23	85.00	—
	13.21	—	—
	3.11	—	—
	10.10	—	—
	62.30	—	—
Cash flow
	-18.32	-9.19	—
	-0.04	-0.02	—
	18.80	-4.24	—
	0.04	0.02	—

Compounded growth

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 9.13%

Quarter	September 2026	June 2026
Promoter %	9.13%	9.13%

Holder	Type	Holding	Previous	Change
Keyur Dipakkumar Shah	Promoter	9.12%	9.12%	0.00%
KAJAL ASHOK JAIN	Public	4.28%	4.28%	0.00%
ASHOK DILIPKUMAR JAIN	Public	4.26%	4.26%	0.00%
SIDDHARTH PODDAR	Public	4.11%	4.11%	0.00%
TEENA KIRTI JAIN	Public	3.26%	3.26%	0.00%
VIBHA R TRIPATHI	Public	2.58%	2.62%	-0.04%
MAHESHBHAI JIVANBHAI RAMANI	Public	2.19%	2.19%	0.00%
GIRISH GANESH SATHE	Public	2.19%	1.94%	+0.25%
SUNITA SANTOSH GOENKA	Public	1.83%	1.83%	0.00%
Kaavya Agrawal	Public	1.67%	1.04%	+0.63%
RAVI BHUSHAN PURI	Public	1.60%	1.18%	+0.42%
ALKA JAYSING TAMBE	Public	1.57%	1.57%	0.00%
JANHAVI SANTOSH GHADGE	Public	1.48%	1.48%	0.00%
BAGESHRI SANTOSH KANITKAR	Public	1.42%	1.42%	0.00%
FALGUNI YOGENDRA TRIVEDI	Public	1.14%	1.14%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
DIPNA PHARMACHEM LIMITED S	10	3.99	5.12	6.90%	—	—	-79.64%

Filings & corporate actions

Recent announcements

Integrated Filing4 Nov 2026 · Company Update / General
Outcome of Board Meeting held today i.e. 4th November, 20264 Nov 2026 · Result / Financial Results
Outcome of Board Meeting held today i.e. 4th November, 20264 Nov 2026 · Board Meeting / Outcome of Board Meeting
Reconstitution of the Committee3 Nov 2026 · Company Update / General
Outcome and Intimation Under Regulation 30 of SEBI (LODR) Regulations, 20153 Nov 2026 · Company Update / Change in Directorate
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 20153 Nov 2026 · Others / Outcome without intimation
Dipna Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) ....31 Oct 2026 · Board Meeting / Board Meeting
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201524 Oct 2026 · Company Update / General
Announcement under Regulation 30 (LODR) - Resignation of Director24 Oct 2026 · Company Update / Resignation of Director
Announcement under Regulation 30 (LODR) - Change in Directorate24 Oct 2026 · Company Update / Change in Directorate
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201524 Oct 2026 · Others / Outcome without intimation
Appointment of Company Secretary and Compliance Officer23 Oct 2026 · Company Update / Appointment of Company Secretary / Compliance Officer
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201523 Oct 2026 · Others / Outcome without intimation
Submission of Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on 30th September, 2026.19 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window30 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Submission of Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended on 30th June, 202615 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Announcement under Regulation 30 (LODR) - Newspaper Publication6 Jul 2026 · Company Update / Newspaper Publication
Submission of Integrated Financials2 Jul 2026 · Company Update / General
Submission of Statment of Deviation and Variation2 Jul 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Submission of Financial Results2 Jul 2026 · Result / Financial Results
Outcome of Board Meeting held today i.e. 2nd July, 20262 Jul 2026 · Board Meeting / Outcome of Board Meeting
Announcement under Regulation 30 (LODR) - Resignation of Director2 Jul 2026 · Company Update / Resignation of Director
Announcement under Regulation 30 (LODR) - Resignation of Director2 Jul 2026 · Company Update / Resignation of Director
Announcement under Regulation 30 (LODR) - Change in Directorate2 Jul 2026 · Company Update / Change in Directorate
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 20152 Jul 2026 · Others / Outcome without intimation
Outcome and Intimation for Rescheduling of Board Meeting to 2nd July, 20261 Jul 2026 · Board Meeting / Outcome of Board Meeting
Dipna Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/07/2026 ,inter alia, to consider and approve Outcome and Intimation for ....1 Jul 2026 · Company Update / Board Meeting Rescheduled
Intimation of Closure of Trading Window30 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Dipna Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/07/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....27 Jun 2026 · Board Meeting / Board Meeting
Annual Secretarial Compliance Report under Reg. 24(A) of SEBI (LODR) Regulations, 2015 for the year ended on 31st March, 202630 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Voting Results for Postal Ballot25 May 2026 · AGM/EGM / Postal Ballot
Post Ballot - Scrutinizer''s Report25 May 2026 · AGM/EGM / Postal Ballot
Announcement under Regulation 30 (LODR)- Newspaper Publication24 Apr 2026 · Company Update / Newspaper Publication
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Notice of Postal Ballot22 Apr 2026 · AGM/EGM / Postal Ballot
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201522 Apr 2026 · Company Update / General
Outcome of the Board meeting and Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201522 Apr 2026 · Others / Outcome without intimation
Compliances - Certificate under Reg. 74(5) of SEBI (DP) Regulations, 201815 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Clarification sought on significant movement in price7 Apr 2026 · Company Update / General
Intimation of Closure of Trading Window31 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has sought clarification from Dipna Pharmachem Ltd on February 23, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....23 Feb 2026 · Company Update / Clarification

Board meetings

4 Nov 2026 Board Meeting - Financial Results